Omar Aimer
Sanofi, Canada
Scientific Tracks Abstracts: J Formul Sci Bioavailab
Pharmaceutical industry, and more particularly pharmacovigilance, has seen the amount of data from individual
safety reports grow exponentially due to the evolution of regulation with more requirements from health
authorities for a better understanding of the safety of pharmaceutical products and ultimately better patient care. This
has led companies to hire more Health Care Professionals to deal with this increased workload. At the same time a
fast development, as in any other field of the industry, of IT solutions or more tendentiously Artificial Intelligence has
occurred with many suppliers offering these services and whose selection must be made successfully to reorganize
pharmacovigilance activities in order to reduce the time and costs of their activities as a result. Hence, collaboration
with IT solution providers selected according to their technical performance but also their level of expertise in
quality and regulatory compliance are essential.
Recent Publications
1. Danysz K, Cicirello S, Mingle E. Artificial Intelligence and the Future of the Drug Safety Professional. Drug
Safety (2019) 42:491â??497.
2. Pitts PJ, Le Louet H, Advancing Drug Safety Through Prospective Pharmacovigilance. Ther Innov Regul Sci.
(2018) 52:400-402.
3. https://www.iqvia.com/blogs/2018/11/pharmacovigilance-automation-has-arrived.
Pharmacovigilance Specialist, Drug Safety and Device officer focus on patient safety and compliance, with an over 15 years of clinical and pharmacovigilance experience at innovative Pharmaceutical Companies (Canada), Health Authorities (ANSM Regional Centers Network in Paris) and in the Hospital environment. Speaker in different local and international events in Europe and North America, recognized for a knowledgeable approach to interacting with multidisciplinary stakeholders within the healthcare community and patients.
Journal of Formulation Science & Bioavailability received 23 citations as per Google Scholar report